As of 2026-07-20, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -1.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 187.38 mil USD. FATE's TTM EBITDA according to its financial statements is -126.89 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 12.5x | 10.4x |
| Forward P/E multiples | 12.3x - 16.1x | 14.8x |
| Fair Price | (19.68) - (20.00) | (20.13) |
| Upside | -807.8% - -819.6% | -824.0% |
| Date | EV/EBITDA |
| 2026-07-17 | -1.48 |
| 2026-07-16 | -1.45 |
| 2026-07-15 | -1.61 |
| 2026-07-14 | -1.61 |
| 2026-07-13 | -1.62 |
| 2026-07-10 | -1.67 |
| 2026-07-09 | -1.68 |
| 2026-07-08 | -1.57 |
| 2026-07-07 | -1.62 |
| 2026-07-06 | -1.61 |
| 2026-07-02 | -1.56 |
| 2026-07-01 | -1.62 |
| 2026-06-30 | -1.43 |
| 2026-06-29 | -1.26 |
| 2026-06-26 | -1.06 |
| 2026-06-25 | -0.92 |
| 2026-06-24 | -1.04 |
| 2026-06-23 | -1.10 |
| 2026-06-22 | -1.09 |
| 2026-06-18 | -1.05 |
| 2026-06-17 | -0.97 |
| 2026-06-16 | -0.94 |
| 2026-06-15 | -1.00 |
| 2026-06-12 | -1.04 |
| 2026-06-11 | -0.98 |
| 2026-06-10 | -0.92 |
| 2026-06-09 | -0.94 |
| 2026-06-08 | -0.94 |
| 2026-06-05 | -0.99 |
| 2026-06-04 | -1.13 |
| 2026-06-03 | -1.13 |
| 2026-06-02 | -1.35 |
| 2026-06-01 | -1.45 |
| 2026-05-29 | -1.51 |
| 2026-05-28 | -1.38 |
| 2026-05-27 | -1.23 |
| 2026-05-26 | -1.09 |
| 2026-05-22 | -1.15 |
| 2026-05-21 | -1.06 |
| 2026-05-20 | -0.90 |
| 2026-05-19 | -0.93 |
| 2026-05-18 | -0.83 |
| 2026-05-15 | -0.85 |
| 2026-05-14 | -0.94 |
| 2026-05-13 | -1.08 |
| 2026-05-12 | -1.15 |
| 2026-05-11 | -1.11 |
| 2026-05-08 | -1.24 |
| 2026-05-07 | -1.26 |
| 2026-05-06 | -1.18 |